Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1991 Nov;50(11):765-8.
doi: 10.1136/ard.50.11.765.

Distribution of the HindIII restriction fragment length polymorphism among patients with systemic lupus erythematosus with different concentrations of CR1

Affiliations

Distribution of the HindIII restriction fragment length polymorphism among patients with systemic lupus erythematosus with different concentrations of CR1

H Satoh et al. Ann Rheum Dis. 1991 Nov.

Abstract

Sixty six patients with systemic lupus erythematosus (SLE) were genotyped using a HindIII restriction fragment length polymorphism identified by CR1.1 cDNA, then were followed up for an average of 50 months to evaluate the stability of their CR1 activities. The gene frequencies for the two alleles which correlate with the numeric expression of CR1 on the erythrocytes were not significantly different between 66 patients with SLE and 52 normal controls. A discrepancy between homozygosity for a high allele and a negative CR1 activity was found in many patients. These patients, however, had significantly lower concentrations of serum complement than did patients with a positive CR1, and some were in an active state of the disease. Furthermore, there were several patients in whom the CR1 activities changed from negative to positive together with an increase in serum complement. Our results suggest that the decreased expression of CR1 on erythrocytes in patients with SLE is not inherited, rather it is a consequence of the disease processes.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Exp Med. 1980 Jul 1;152(1):20-30 - PubMed
    1. J Exp Med. 1982 May 1;155(5):1427-38 - PubMed
    1. Blood. 1979 May;53(5):799-811 - PubMed
    1. J Mol Biol. 1975 Nov 5;98(3):503-17 - PubMed
    1. J Immunol. 1985 Oct;135(4):2687-94 - PubMed

MeSH terms

Substances